Advanced non-viral cationic lipids for siRNA-based cancer therapy
Raut Bholakant, Wei Chen
siRNA based cancer therapy is a powerful modality for cancer treatment. With the recent FDA approval of Patisiran and Givosiran, siRNA mediated nucleic acid therapy is undergoing a transition from research to clinical space. The primary obstacle for siRNA-based cancer therapy is the delivery of oligonucleotide payloads into the cytoplasm of tumor cells. The success of siRNA-based therapy mainly depends upon the design of carrier systems. Currently, cationic lipids-based vehicles have been widely used to maximize the delivery efficiency of siRNA into the various tumor cells. The objective of this review is to provide an overview of cationic lipid-based carriers in recently published researches focusing on their in vitro and in vivo studies to provide future research direction to siRNA-based cancer therapy.